Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Biohaven Pharma (BHVN) Tops Q2 EPS by 6c, Revenues Beat
August 10, 2020 7:47 AM EDTBiohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($2.55), $0.06 better than the analyst estimate of ($2.61). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $7.65 million.
Vlad Coric, M.D. Chief Executive Officer, commented, "This has been an... More
